File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Isoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/β-Catenin

TitleIsoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/β-Catenin
Authors
KeywordsTriple-Negative Breast Cancer
Isoliquiritigenin
Epithelial-Mesenchymal Transition
MiR-200c
Issue Date2021
PublisherWorld Scientific Publishing Co Pte Ltd. The Journal's web site is located at http://www.worldscinet.com/ajcm/ajcm.shtml
Citation
The American Journal of Chinese Medicine, 2021, v. 49 n. 2, p. 505-523 How to Cite?
AbstractTriple-negative breast cancer (TNBC) is the subtype of breast cancer with more aggressive growth and metastasis and without efficient therapies. Hence, it is worthwhile to search for potential effective drug candidates. According to our previous study, isoliquiritigenin (ISL) exerted a potent anticancer effect on breast cancer proliferation. Its effect on TNBC growth, metastasis and mechanism deserves further investigation. In this study, PCR array screened a significant increase of miR-200c in BT-549 and MDA-MB-231 cells after ISL treatment, and ISH exerted that miR-200c was expressed at a low level in breast cancer tissue of patients. We also found that ISL could up-regulate miR-200c, resulting in the inhibition of epithelial-mesenchymal transition. Meanwhile, ISL could inhibit metastasis and tumor growth in nude mice models through the increase of miR-200c. Further study displayed that ISL decreased c-Jun expression through the increase of miR-200c. Interestingly, we also detected that ISL might increase miR-200c expression through the demethylation of miR-200c promoter region. These findings indicated that ISL could be potentially developed as a novel drug candidate for TNBC in microRNA-based cancer therapies.
Persistent Identifierhttp://hdl.handle.net/10722/308489
ISSN
2023 Impact Factor: 4.8
2023 SCImago Journal Rankings: 1.025
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorPENG, F-
dc.contributor.authorTang, H-
dc.contributor.authorDu, J-
dc.contributor.authorChen, J-
dc.contributor.authorPeng, C-
dc.date.accessioned2021-12-01T07:54:02Z-
dc.date.available2021-12-01T07:54:02Z-
dc.date.issued2021-
dc.identifier.citationThe American Journal of Chinese Medicine, 2021, v. 49 n. 2, p. 505-523-
dc.identifier.issn0192-415X-
dc.identifier.urihttp://hdl.handle.net/10722/308489-
dc.description.abstractTriple-negative breast cancer (TNBC) is the subtype of breast cancer with more aggressive growth and metastasis and without efficient therapies. Hence, it is worthwhile to search for potential effective drug candidates. According to our previous study, isoliquiritigenin (ISL) exerted a potent anticancer effect on breast cancer proliferation. Its effect on TNBC growth, metastasis and mechanism deserves further investigation. In this study, PCR array screened a significant increase of miR-200c in BT-549 and MDA-MB-231 cells after ISL treatment, and ISH exerted that miR-200c was expressed at a low level in breast cancer tissue of patients. We also found that ISL could up-regulate miR-200c, resulting in the inhibition of epithelial-mesenchymal transition. Meanwhile, ISL could inhibit metastasis and tumor growth in nude mice models through the increase of miR-200c. Further study displayed that ISL decreased c-Jun expression through the increase of miR-200c. Interestingly, we also detected that ISL might increase miR-200c expression through the demethylation of miR-200c promoter region. These findings indicated that ISL could be potentially developed as a novel drug candidate for TNBC in microRNA-based cancer therapies.-
dc.languageeng-
dc.publisherWorld Scientific Publishing Co Pte Ltd. The Journal's web site is located at http://www.worldscinet.com/ajcm/ajcm.shtml-
dc.relation.ispartofThe American Journal of Chinese Medicine-
dc.rightsFor preprints : Preprint of an article published in [Journal, Volume, Issue, Year, Pages] [Article DOI] © [copyright World Scientific Publishing Company] [Journal URL] For postprints : Electronic version of an article published as [Journal, Volume, Issue, Year, Pages] [Article DOI] © [copyright World Scientific Publishing Company] [Journal URL]-
dc.subjectTriple-Negative Breast Cancer-
dc.subjectIsoliquiritigenin-
dc.subjectEpithelial-Mesenchymal Transition-
dc.subjectMiR-200c-
dc.titleIsoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/β-Catenin-
dc.typeArticle-
dc.identifier.emailChen, J: abchen@hkucc.hku.hk-
dc.identifier.authorityChen, J=rp01316-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1142/S0192415X21500233-
dc.identifier.pmid33641651-
dc.identifier.scopuseid_2-s2.0-85101898782-
dc.identifier.hkuros330441-
dc.identifier.volume49-
dc.identifier.issue2-
dc.identifier.spage505-
dc.identifier.epage523-
dc.identifier.isiWOS:000630413300011-
dc.publisher.placeSingapore-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats